---
title: "Neurodevelopmental deficits in under‑5 children with sickle cell disease in Eastern Uganda"
id: "plos-one-11-neurodevelopment-among-children-under-five-years-with-sickle-cell-disease-in"
canonical_url: "https://medichelpline.com/clinical-feed/plos-one-11-neurodevelopment-among-children-under-five-years-with-sickle-cell-disease-in"
content_type: "clinical_feed_article"
specialty: "Pediatrics"
source_name: "PLOS ONE (Medicine)"
source_url: "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0363134"
published_at: "2026-11-18T14:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Neurodevelopmental deficits in under‑5 children with sickle cell disease in Eastern Uganda
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/plos-one-11-neurodevelopment-among-children-under-five-years-with-sickle-cell-disease-in
- **Specialty:** [Pediatrics](https://medichelpline.com/clinical-feed/pediatrics.md)
- **Primary Source:** PLOS ONE (Medicine)
- **Source URL:** [Original Journal Publication](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0363134)
- **Published At:** 2026-11-18T14:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- The investigators performed a cross‑sectional comparison of neurodevelopment among 350 children under five years (117 with **sickle cell disease**, 233 without) at Mbale Regional Referral Hospital, Eastern Uganda. - Neurodevelopment was the primary outcome and was measured with the **Malawi Developmental Assessment Tool** (MDAT), covering language, social, gross motor and fine motor domains. - Independent sample t‑tests compared development‑for‑age z‑scores (DAZ) between groups; inverse probability of treatment weighting (IPTW) was used to estimate the effect of disease status on development. - Median participant age was 40.9 months (IQR 27.8–54.3 months). Children with SCD had lower overall DAZ; the reported unadjusted difference was 0.89 lower DAZ versus community controls. - IPTW produced an average exposure effect of −0.87 (95% CI −1.19 to −0.55); the average exposure effect among the exposed was −0.62 (95% CI −1.01 to −0.23), according to the authors. - Domain‑level deficits were observed across social, gross motor, fine motor and language domains in children with SCD compared with peers without SCD. - Within the SCD group, children not on **hydroxyurea** had lower DAZ in the social and language domains (0.4 lower) compared with those receiving hydroxyurea, as reported by the study team. - The team noted health‑system gaps relevant to interpretation: hydroxyurea uptake and documentation varied across facilities, and transcranial Doppler screening was not routinely available at the study site during data collection. - Investigators recommend routine neurodevelopmental screening integrated into SCD care to enable early detection and intervention; the study also signals remaining data gaps on implementation, long‑term trajectories, and causal pathways.
## Clinical Analysis & Structured Key Points
Neurodevelopment among children under five years with sickle cell disease in Eastern Uganda: A propensity score analysis | PLOS One Browse Subject Areas ? Click through the PLOS taxonomy to find articles in your field. For more information about PLOS Subject Areas, click here . Article Authors Metrics Comments Media Coverage Reader Comments Figures Figures Abstract Aim We compared neurodevelopment among children under-five years with and without sickle cell disease in eastern Uganda. Methods We conducted a cross-sectional study between March and September 2025 at the pediatric sickle cell clinic of Mbale Regional Referral Hospital. We included 350 children under five years (117 with sickle cell disease and 233 without sickle cell disease). The primary outcome was neurodevelopment assessed using the Malawi Development Assessment Tool. We performed independent sample t -tests to compare development for age z-scores between children with and without sickle cell disease. We used inverse probability of treatment weighting analyses to calculate the effect of sickle cell disease on neurodevelopment. Results The median age of the children was 40.9 months (interquartile range 27.8 to 54.3 months). Children with sickle cell disease had 0.89 lower DAZ scores compared to their peers without sickle cell disease. Among the children with sickle cell disease, those not enrolled on hydroxyurea had 0.4 lower DAZ scores in the social and language domains compared to those on hydroxyurea. The average exposure effect, obtained from the inverse probability of treatment weighting analyses, was −0.87, 95% CI [−1.19, −0.55] and the average exposure effect among the exposed was – 0.62 95% CI [- 1.01, – 0.23]. Conclusion Children with sickle cell disease had lower developmental scores across all domains (social, gross motor, fine motor and language) compared to community controls. These findings highlight the developmental vulnerability associated with sickle cell disease in early childhood. Efforts towards timely screening and management of developmental delays among children are needed to improve their quality of life and long-term development. This may be through integration of neurodevelopmental screening into routine sickle cell disease care. Citation: Maumbe B, Mukunya D, Nambozo B, Oguttu F, Abeso J, Mutonyi S, et al. (2026) Neurodevelopment among children under five years with sickle cell disease in Eastern Uganda: A propensity score analysis. PLoS One 21(11): e0363134. https://doi.org/10.1371/journal.pone.0363134 Editor: Chibuikem Anthony Ikwuegbuenyi, Weill Cornell Medicine, UNITED STATES OF AMERICA Received: May 14, 2026; Accepted: November 4, 2026; Published: November 18, 2026 Copyright: © 2026 Maumbe et al. This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Data Availability: The minimal data set has uploaded as supporting information. Funding: This research study was funded by “National Institutes of Health’s, FOGARTY INTERNATIONAL CENTER to “Enhancing Research Capacity for Sickle Cell Disease and related NCDs across the Lifespan in Uganda, Enrich Project under award number D43TW012466. The funders had no role in the design of the study, implementation and data analysis. Competing interests: The authors have declared that no competing interests exist. Introduction Sickle cell disease (SCD) is one of the most common genetic blood disorders worldwide with an estimated 300,000–500,000 infants born annually with the condition. Low-middle-income countries (LMICs) especially in sub-Saharan Africa bear the highest burden and account for more than 75% of the global cases. In 2021, the estimated total SCD mortality burden was approximately 370,000. Among children under five years, there were about 80,000 deaths, ranking total SCD mortality as 12 th across all diseases ranked by the Global Burden of Disease Consortia [ 1 ]. In Uganda, the prevalence of sickle cell disease ranges between 0.2% and 1% across regions. An estimated 15000 babies are born with SCD each year [ 2 ]. Despite this high burden, health systems in LMICs, including Uganda, face significant challenges in providing comprehensive care. Such limited care probably contributes to the high morbidity and mortality among affected children. Studies in the general pediatric population indicate that approximately 14% of children in LMICs experience neurodevelopmental delays [ 3 ]. This burden is likely much higher among children with SCD, though it remains poorly documented. Among those with SCD, the burden of neurodevelopmental delays is likely much higher, but not well documented. Recurrent vaso-occlusive crises [ 4 ], severe anemia, infections, and organ damage are common in children with SCD, and together these contribute to poor health outcomes and reduced life expectancy. Beyond physical complications, children with SCD suffer cerebral infarcts [ 5 ] and silent strokes [ 6 ] which negatively impact the neurocognitive and development of children leading to delays in language, motor, and social development [ 7 – 13 ]. These impairments affect school readiness, educational attainment, and overall quality of life. Families also face psychosocial and economic burdens due to frequent hospitalization and caregiving demands, reduced productivity further worsening the negative impact on child development [ 14 , 15 ]. Several interventions including newborn screening [ 16 ], prophylactic antibiotics, vaccination, and hydroxyurea therapy have been shown to reduce morbidity and improve survival among children with SCD [ 17 ]. Despite these advances, there is paucity of data on the neurodevelopment of children with SCD in eastern Uganda, yet they are exposed to multiple biological and socio-environmental risks such as poverty, limited healthcare access, and inadequate early childhood stimulation. Without adequate data, opportunities for early detection and timely intervention may be missed, potentially resulting in poor developmental outcomes. Early identification of neurodevelopmental delays is therefore essential, as it enables timely interventions and promotes optimal developmental trajectories. In this study, we compared the neurodevelopment among children under-five years with and without SCD in Eastern Uganda. Methods Study design We conducted a cross-sectional study among children under five years of age between March 2025 to September 2025. Study setting The study was conducted at the pediatric sickle cell clinic of Mbale Regional Referral Hospital (MRRH), a public tertiary facility in eastern Uganda. The hospital serves as a referral center for six major general hospitals and multiple health sub‑districts in the Elgon region, with a catchment population of more than four million people. The outpatient sickle cell clinic is operated by a consultant pediatrician, pediatric residents, clinical officers, and nurses. It operates once a week and provides routine follow‑up care, including medication refills and clinical assessments, for children with SCD who are not in painful crises or sick. The ministry of health in Uganda has strengthened national SCD care through the adoption of several key interventions. Hydroxyurea is now recommended and freely provided as part of routine management under the Uganda clinical guidelines (2023), although uptake and documentation vary across facilities. Transcranial Doppler screening is also recommended for stroke risk assessment, but it was not routinely available at the study site during the data‑collection period. Participants The study participants were children under five years of age with and without SCD. Children with SCD were recruited from the pediatric sickle cell clinic at MRRH. For the comparison group, we enrolled siblings, close relatives, or neighbours within the same age range. We excluded children with SCD who had other chronic illnesses such as congenital heart disease or epilepsy. Variables The primary outcome was neurodevelopment assessed using the Malawi Developmental Assessment Tool (MDAT), a validated tool for evaluating child development across four domains, fine motor, gross motor, language and social development in children from birth to six years in low‑resource settings [ 18 ]. The main exposure was sickle cell disease status of the child. Additional co-variates included child‑level factors such as age, sex, nutritional status, preterm birth, food diversity in diet, immunisation history, breastfeeding history, living with siblings, and use of hydroxyurea. We also collected sociodemographic and economic characteristics of the primary caregiver, including age, marital status, education level, number of siblings, household wealth, and history of birth complications. Data sources/measurements Neurodevelopment was assessed using the MDAT mounted on Kobo Toolbox data collection software. The MDAT is a culturally relevant developmental screening tool designed specifically for use in rural African settings, consisting of four domains language, social, gross motor, and fine motor development with 34 items in each domain (136 items total). The validation tests of the MDAT tool indicate a high sensitivity (97%) and specificity (82%) [ 19 ]. To perform the test, a trained assessor elicits a series of actions from the child and asks the caregiver questions about the child, with pictorial aids used to support understanding of tasks and questions. In our study, five study research assistants who are qualified nurses and midwives underwent a five-day physical training on MDAT by an MDAT certified trainer prior to data collection. Items are scored as “pass,” “fail,” or, if the child is uncooperative, “don't know.” Gross motor, fine motor, and language domains are assessed through direct observation of the child, while social development is assessed through questions posed to the caregiver. Children with SCD were identified through the hospital registers of the SCD clinic at the pediatric unit of Mbale Regional Referral Hospital, where they were already receiving clinical care; they were not tested as part of the current study. SCD status is usually determined through a two-step process. Screening for SCD is conducted at public health facilities using the sickling test, and samples which turn positive are shipped to the Central Public Health Laboratories (CPHL) under the Ministry of Health for confirmatory hemoglobin electrophoresis. The comparison group children, who did not have a prior SCD diagnosis, were tested for sickle cell genotype using blood dry spots that were shipped to CPHL for Hb electrophoresis as part of this study to rule out misclassification of exposure status. Additional exposure variables were obtained through caregiver self‑report. The child’s age was recorded in months as a continuous variable, and sex was categorized as male or female. Other child‑level characteristics included preterm birth (yes/no), weight‑for‑length/height status (wasting, normal, overweight), dietary diversity (yes/no), full immunization for age (yes/no), ever breastfed (yes/no), and living with siblings under five years (yes/no) and use of hydroxyurea (yes/no) among the children with SCD. Caregiver‑level variables included primary caregiver (mother, father, other relative), caregiver age (18–34, 35–44, ≥ 45 years), education level (none, primary, secondary, tertiary), marital status (married/not married), and place of residence (rural/urban). Household wealth was assessed using principal component analysis and categorized as poor, middle, or rich tertiles. Bias We did not blind the outcome assessors because children with sickle cell disease have salient physical features that make blinding impractical. Sample size The sample size was calculated using Open-Epi ( http://www.openepi.com ) for comparison of two independent means, assuming 80% power, a 95% confidence level, and a 2:1 allocation ratio of children without SCD to those with SCD. Using a mean difference of 0.4 in neurodevelopment scores and a common standard deviation of 1.0 from a previous study at Mulago Hospital sickle cell clinic in Kampala [ 20 ], the estimated minimum sample size was 222 children (74 with SCD and 148 without SCD). However, a total of 350 children were enrolled (117 with SCD and 233 without SCD) to improve the precision of the estimates and increase statistical power. Study procedures We identified children under five years of age living with sickle cell disease and attending the pediatric sickle cell clinic at MRRH. Primary caregivers were approached and invited to a private space where trained research assistants (nurses and midwives) obtained written informed consent. Thereafter, an electronic structured questionnaire was administered to collect relevant sociodemographic, socio-economic and clinical information from the caregiver. Each child was then assessed for neurodevelopment using the MDAT across four domains: gross motor, fine motor, language (through direct observation), and social development (through caregiver interview). The primary caregivers to the children with SCD were also asked whether they had children of similar ages without SCD in their households and relatives or neighborhoods. The primary caregivers provided the study team with telephone contacts of the parents/caregivers to those children without SCD. These parents/caregivers were contacted by telephone and invited to participate in the study. For each child with SCD assessed, we invited two children without SCD of similar age from their communities as a comparison group. Written informed consent was obtained from each of the caregivers before any interviews and neurodevelopment assessment were conducted. Weight was measured three times using a digital SECA weighing scale, and length was measured using a length mat. Mid‑upper arm circumference (MUAC) was measured using a pediatric MUAC tape at the midpoint between the olecranon and acromion of the left arm using a standard tape. Data analysis We analysed data in Stata software version 18.0 (Stata Corp; College Station, TX, USA). We summarized continuous variables as means (standard deviations) and medians (interquartile ranges). The categorical variables were summarized as proportions. We performed independent sample t-tests to assess the differences in the overall mean DAZ scores and across domains between children with and without SCD. Mean differences with corresponding 95% confidence intervals (CIs) are reported. IPTW was used to estimate multiple treatment effects, including the average treatment effect (ATE), hereafter correctly termed the average exposure effects, and the average treatment effect on the treated (ATET), hereafter correctly termed the average exposure effects among the exposed. For the Inverse Probability of Treatment Weighting (IPTW) approach, we included variables that increased the risk of the outcome, even though they did not affect exposure (SCD). These included parental education, wealth index, age of the primary caregiver, relationship of the primary caregiver to the child, marital status, residence, age of the child, child’s sex, nutrition status of the child, dietary diversity, siblings under five years, and immunization status. To address potential misclassification in the IPTW models, we conducted a sensitivity analysis using inverse probability weighted regression adjustment (IPWRA) and augmented inverse probability of treatment weighting (AIPW). After these analyses, we assessed covariate balance using standardized mean differences, variance ratios, and overlap plots. Propensity score distribution. The distribution of the estimated propensity scores for children with and without SCD ( Fig 1 ). Download: PNG larger image TIFF original image Fig 1. A density plot showing the overlap of propensity scores between children with and without SCD. https://doi.org/10.1371/journal.pone.0363134.g001 The density plots reveal a high degree of overlap between the two groups. Specifically, both groups are represented across the propensity score range of approximately 0.2 to 0.95. This overlap suggests that children with SCD had counterparts with similar baseline characteristics in the non-SCD group, satisfying the positivity assumption required for valid IPTW estimation. All models (IPTW, AIPW, and IPWRA) were adjusted for parental education, wealth index, caregiver age/relationship, marital status, residence, child age/sex, nutritional status (WHZ), dietary diversity, presence of siblings <5 years, and immunization status. Ethical considerations We obtained ethical approval to conduct the study from the Busitema University Faculty of Health Sciences Research Ethics Committee (BUFHS-REC-2024–217). We also sought administrative clearance from Mbale Regional Referral Hospital to conduct the study at the pediatric unit. Written informed consent was obtained from all caregivers and was obtained before data collection. Children identified with neurodevelopmental delay were linked to care within the hospital for further assessment and management. Results Participants characteristics The median child age was 40.9 months, and interquartile range (27.8–54.3) months. Most of the primary caregivers of children, 71.7% (251/350) were mothers. Most of the primary caregivers, 70.3% (246/350) were aged 18–34 years. Seventy-two per cent (253/350) of the participants resided in rural areas, and the distribution across the wealth tertiles was comparable ( Table 1 ). Download: PNG larger image TIFF original image Table 1. Characteristics of primary caregivers to children under five years with and without SCD in Eastern Uganda. https://doi.org/10.1371/journal.pone.0363134.t001 Characteristics of children A third of the children, 33.4% (117/350) had SCD. Fifty seven percent (119/350) of the children were aged 3–5 years, and fifty three percent (185/350) were male ( Table 2 ). Among the children with sickle cell disease, 70.9% (83/117) were enrolled on hydroxyurea and almost all of them 98.3% (115/117) were taking folic acid supplements. Among the controls tested for SCD, 71.8% had the Hb AA genotype, 18.03% had Hb AS, and 0.02% had Hb AV. Download: PNG larger image TIFF original image Table 2. Characteristics of children under five years with and without SCD in Eastern Uganda. https://doi.org/10.1371/journal.pone.0363134.t002 Neurodevelopment among children Children with SCD had 0.89 lower mean DAZ scores compared to children without SCD ( Table 3 ). Children with SCD had lower mean DAZ scores in all the domains as compared to children without SCD ( Table 3 ). Children not on hydroxyurea had 0.4 lower mean DAZ scores for the social and language domains compared to those on hydroxyurea ( Table 4 ). Download: PNG larger image TIFF original image Table 3. Comparison of DAZ Scores for neurodevelopment between children with and without SCD in Eastern Uganda. https://doi.org/10.1371/journal.pone.0363134.t003 Download: PNG larger image TIFF original image Table 4. Comparison of DAZ scores for neurodevelopment among children with SCD on hydroxyurea versus those not on hydroxyurea in eastern Uganda. https://doi.org/10.1371/journal.pone.0363134.t004 Effect of sickle cell disease on the neurodevelopment of children The average exposure effect was −0.87, 95% CI [−1.19, −0.55] ( Table 5 ). The average exposure effect among the exposed was – 0.62 [- 1.01, – 0.23]. Download: PNG larger image TIFF original image Table 5. Treatment effects (with 95% confidence intervals) of SCD on neurodevelopment among children under five years in Eastern Uganda. https://doi.org/10.1371/journal.pone.0363134.t005 Discussion Our study observed a difference in neurodevelopment between children with SCD and their peers without SCD. Children with SCD had 0.89 lower DAZ scores in all domains c
## Related Clinical Research

- [Out-of-hospital pediatric asthma attack care in Martinique: pre-hospital treatment gaps](https://medichelpline.com/clinical-feed/medrxiv-2-evaluation-of-out-of-hospital-management-of-asthma-attacks-prior-to.md)
- [Pittsburgh Claims Top Two National Leaders of Impact Honors](https://medichelpline.com/clinical-feed/aha-news-0-pittsburgh-sweeps-national-leaders-of-impact-honors.md)
- [ACROSSS study protocol: sleep patterns before and after acute cardiovascular events](https://medichelpline.com/clinical-feed/medrxiv-10-the-acrosss-study-the-role-of-sleep-characteristics-before-and-after-a.md)
- [Exercise Prescriptions for Concussion Recovery: An Urgent Call to Action](https://medichelpline.com/clinical-feed/stat-news-2-opinion-more-doctors-should-prescribe-exercise-after-a-concussion.md)
- [U.S. POINTER: Structured lifestyle program slows brain aging and cardiometabolic risk over 24 mont](https://medichelpline.com/clinical-feed/medical-news-today-0-combining-physical-mental-and-social-habits-slows-brain-aging-in-2-year-trial.md)

## Navigation
- [← Back to Pediatrics Feed](https://medichelpline.com/clinical-feed/pediatrics.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.